Hepatitis C–safe antiviral plan for heart transplant recipients
Part of Heart & circulation clinical trials.
This Phase 2 trial tests giving newer hepatitis C medicines in a careful way to people getting a heart transplant who currently do not have hepatitis C in their blood. The goal is to lower hepatitis C infection risk from donated organs while keeping transplant outcomes safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign written consent and are able to follow study instructions
- You are 18 or older
- You are listed for a heart-only transplant (not combined with other organs)
- You do not have hepatitis C in your blood, or—if you previously had it—you were fully cleared and your recent tests are negative
- You do not have ongoing hepatitis B infection and do not have significant liver disease like cirrhosis or portal high blood pressure
- You are not pregnant, not HIV-positive, and do not have severe kidney failure needing dialysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special machine that preserves donor hearts for longer periods before transplant. It may help people waiting for a heart transplant who need a heart from a donor that may be older or has some heart risks.
This study tests antiviral medicine given around the time of a kidney transplant to prevent hepatitis C infection when the donor has hepatitis C. It may help uninfected recipients stay hepatitis C–free after receiving the kidney.
This study tests whether a drug called belatacept can safely help your body accept a new heart without rejecting it, and may reduce the need for other strong immune-suppressing medicines. If you are getting a heart transplant for the first time and have certain immune markers, this trial may be an option for you.
This trial follows people who receive a heart from a donor whose blood tested positive for hepatitis C. It also includes people getting a heart transplant again, and it aims to learn about outcomes and safety for these specific transplant situations.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This study looks at factors that affect heart health after a liver transplant. It may help doctors better predict and manage heart problems in people with end-stage liver disease who are getting a new liver.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.